FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134461285> ?p ?o ?g. }

• W3134461285 endingPage "397" @default.
• W3134461285 startingPage "397" @default.
• W3134461285 abstract "397 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy (Cx) or chemoradiation (CRT) is the standard of care for urothelial carcinoma (UC) pts with muscle invasive bladder cancer (MIBC). Both Cx and CRT have potential short and long-term toxicity and QOL implications. Mutations in DNA damage repair/response genes are associated with pathologic downstaging after NAC. Methods: We conducted a phase II, multi-institutional clinical trial (NCT02710734) to evaluate a risk-adapted approach to treatment of MIBC. Pts with cT2-T3N0M0 UC of the bladder, ECOG PS 0-1 and CrCl≥50 mL/min, underwent NAC with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). Pre-NAC TURBT specimens were sequenced (Caris Life Sciences) for mutations (pathogenic or VUS) in ATM, ERCC2, FANCC or RB1. Pts with at least one mutation and no clinical evidence of disease by restaging TUR and imaging post-NAC began pre-defined active surveillance (AS). Remaining pts underwent bladder-directed therapy: intravesical therapy ( < cT2 post-NAC), CRT or Cx. The primary endpoint was metastasis-free survival (MFS) at 2 years which is not mature. We herein report key interim results of clinically-meaningful intermediate endpoints. Results: Seventy-one (ITT) pts were enrolled over 33 months at four academic centers. Median age was 70 years (47-83), 74% were male, 92% Caucasian, 81% ECOG PS 0 and 79% cT2. 90% completed 3 cycles of NAC and with 17% grade 3-4 TRAEs and one death during AMVAC. At the time of data cut-off (September 11, 2020), for the ITT pts, 32 pts have had a Cx, 5 underwent CRT and 7 underwent intravesical therapy, at some point during the trial. Thirty-three pts (46%) had a mutation of interest and 28 pts (39%) started AS (2 of the 28 pts on AS did not have a mutation but elected to start AS after achieving cT0 post AMVAC). 76% of those with a mutation were cT0 at post-NAC TURBT. With a median follow-up of 14.9 mo (range: 3.1-35.3 mo), 14 AS pts recurred (50%). Of the 14 recurrences, 2 recurred with locally advanced or metastatic disease and have died, 5 had MIBC with one eventual metastatic recurrence, and 7 had NMIBC. Six (14%) non-AS pts have died. Out of the 40 pts who did not go to upfront Cx [AS (N = 28), CRT (N = 5), intravesical tx (N = 7)], 3 (7.5%) (all in the AS group) went on to Cx later. The bladder preservation rate is 55% for ITT pts and 89% for the AS group. In the AS cohort, mutations were seen in RB1 (50%), ATM (42%), ERCC2 (31%), FANCC (4%) with lowest rate for recurrence in ERCC2 (25% recurrence) vs RB1 (62% recurrence). Conclusions: Interim results of a phase II trial of risk enabled therapy utilizing a selection of clinical and genomic factors in pts with cT2-T3 MIBC demonstrates a 50% rate of any UC recurrence and a 11% rate of locally advanced/metastatic disease in the AS group. 89% of AS pts have retained their bladder. Follow-up continues for the primary endpoint of 2-year MFS. Clinical trial information: NCT02710734." @default.
• W3134461285 created "2021-03-15" @default.
• W3134461285 creator A5011122559 @default.
• W3134461285 creator A5020184536 @default.
• W3134461285 creator A5030403516 @default.
• W3134461285 creator A5032422193 @default.
• W3134461285 creator A5033372450 @default.
• W3134461285 creator A5037162298 @default.
• W3134461285 creator A5043554307 @default.
• W3134461285 creator A5043618026 @default.
• W3134461285 creator A5044979250 @default.
• W3134461285 creator A5048218662 @default.
• W3134461285 creator A5049646055 @default.
• W3134461285 creator A5049901305 @default.
• W3134461285 creator A5051789976 @default.
• W3134461285 creator A5057775605 @default.
• W3134461285 creator A5065101092 @default.
• W3134461285 creator A5065848215 @default.
• W3134461285 creator A5075320625 @default.
• W3134461285 creator A5079166812 @default.
• W3134461285 creator A5080057051 @default.
• W3134461285 creator A5091629756 @default.
• W3134461285 date "2021-02-20" @default.
• W3134461285 modified "2023-10-09" @default.
• W3134461285 title "A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis." @default.
• W3134461285 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.397" @default.
• W3134461285 hasPublicationYear "2021" @default.
• W3134461285 type Work @default.
• W3134461285 sameAs 3134461285 @default.
• W3134461285 citedByCount "25" @default.
• W3134461285 countsByYear W31344612852021 @default.
• W3134461285 countsByYear W31344612852022 @default.
• W3134461285 countsByYear W31344612852023 @default.
• W3134461285 crossrefType "journal-article" @default.
• W3134461285 hasAuthorship W3134461285A5011122559 @default.
• W3134461285 hasAuthorship W3134461285A5020184536 @default.
• W3134461285 hasAuthorship W3134461285A5030403516 @default.
• W3134461285 hasAuthorship W3134461285A5032422193 @default.
• W3134461285 hasAuthorship W3134461285A5033372450 @default.
• W3134461285 hasAuthorship W3134461285A5037162298 @default.
• W3134461285 hasAuthorship W3134461285A5043554307 @default.
• W3134461285 hasAuthorship W3134461285A5043618026 @default.
• W3134461285 hasAuthorship W3134461285A5044979250 @default.
• W3134461285 hasAuthorship W3134461285A5048218662 @default.
• W3134461285 hasAuthorship W3134461285A5049646055 @default.
• W3134461285 hasAuthorship W3134461285A5049901305 @default.
• W3134461285 hasAuthorship W3134461285A5051789976 @default.
• W3134461285 hasAuthorship W3134461285A5057775605 @default.
• W3134461285 hasAuthorship W3134461285A5065101092 @default.
• W3134461285 hasAuthorship W3134461285A5065848215 @default.
• W3134461285 hasAuthorship W3134461285A5075320625 @default.
• W3134461285 hasAuthorship W3134461285A5079166812 @default.
• W3134461285 hasAuthorship W3134461285A5080057051 @default.
• W3134461285 hasAuthorship W3134461285A5091629756 @default.
• W3134461285 hasConcept C121608353 @default.
• W3134461285 hasConcept C126322002 @default.
• W3134461285 hasConcept C126894567 @default.
• W3134461285 hasConcept C141071460 @default.
• W3134461285 hasConcept C143998085 @default.
• W3134461285 hasConcept C203092338 @default.
• W3134461285 hasConcept C2775910329 @default.
• W3134461285 hasConcept C2776694085 @default.
• W3134461285 hasConcept C2778239845 @default.
• W3134461285 hasConcept C2778292576 @default.
• W3134461285 hasConcept C2780352672 @default.
• W3134461285 hasConcept C530470458 @default.
• W3134461285 hasConcept C535046627 @default.
• W3134461285 hasConcept C61943457 @default.
• W3134461285 hasConcept C71924100 @default.
• W3134461285 hasConceptScore W3134461285C121608353 @default.
• W3134461285 hasConceptScore W3134461285C126322002 @default.
• W3134461285 hasConceptScore W3134461285C126894567 @default.
• W3134461285 hasConceptScore W3134461285C141071460 @default.
• W3134461285 hasConceptScore W3134461285C143998085 @default.
• W3134461285 hasConceptScore W3134461285C203092338 @default.
• W3134461285 hasConceptScore W3134461285C2775910329 @default.
• W3134461285 hasConceptScore W3134461285C2776694085 @default.
• W3134461285 hasConceptScore W3134461285C2778239845 @default.
• W3134461285 hasConceptScore W3134461285C2778292576 @default.
• W3134461285 hasConceptScore W3134461285C2780352672 @default.
• W3134461285 hasConceptScore W3134461285C530470458 @default.
• W3134461285 hasConceptScore W3134461285C535046627 @default.
• W3134461285 hasConceptScore W3134461285C61943457 @default.
• W3134461285 hasConceptScore W3134461285C71924100 @default.
• W3134461285 hasFunder F4320332523 @default.
• W3134461285 hasIssue "6_suppl" @default.
• W3134461285 hasLocation W31344612851 @default.
• W3134461285 hasOpenAccess W3134461285 @default.
• W3134461285 hasPrimaryLocation W31344612851 @default.
• W3134461285 hasRelatedWork W2012557700 @default.
• W3134461285 hasRelatedWork W2125696407 @default.
• W3134461285 hasRelatedWork W2386417211 @default.
• W3134461285 hasRelatedWork W2401969674 @default.
• W3134461285 hasRelatedWork W2598074874 @default.
• W3134461285 hasRelatedWork W2603025253 @default.
• W3134461285 hasRelatedWork W2980761415 @default.
• W3134461285 hasRelatedWork W3144473405 @default.
• W3134461285 hasRelatedWork W3202515919 @default.

• next